Mizuho lowered the firm’s price target on Glaukos (GKOS) to $130 from $150 and keeps an Outperform rating on the shares. The firm says the company’s Q2 report and 2025 outlook remain supportive of its iDose sales ramp estimates, but is being offset by near-term portfolio dynamics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos’s iDose Success and Promising Growth Potential Drive Buy Rating
- Glaukos Corporation Reports Strong Q2 2025 Growth
- Closing Bell Movers: Microsoft jumps 9%, Meta up 12% on earnings beats
- Glaukos Reports Record Q2 Sales, Raises 2025 Guidance
- Glaukos raises Fy25 revenue view to $480M-$4/86M from $475M-$485M